Craig A. Barbarosh

October 14, 2026

Sabra Health Care REIT analysts lower price targets. UBS kept a neutral rating on Sabra Health Care REIT but reduced its price target to $20. Barclays also maintained an equal‑weight stance while cutting its target to $21. Both revisions suggest a more modest outlook for the REIT. The new targets sit near the stock’s recent support level around $19.70.

September 26, 2026

Evolent Health Faces Critique, Wins Telephonic Interpretation Contract. Recent coverage highlights two contrasting stories for Evolent Health. A Yahoo piece lists three reasons to avoid the stock, while another reports that TransPerfect was chosen to provide enterprise‑wide telephonic interpretation services for Evolent. The company’s price is near its 52‑week low and below the average analyst target of $5.77, adding context to the mixed sentiment.

September 28, 2026

Lifecore Biomedical to be acquired by Webster Equity Partners. Lifecore Biomedical has announced it will be acquired by Webster Equity Partners in a deal valued at up to $663.7 million. Shareholders may receive up to $9.67 per common equivalent, combining cash and contingent value rights based on performance milestones. This transaction is significant as it represents a full exit for the company, with the potential payout exceeding the current average analyst target of $6.75.